INTRODUCTION
Lysine biosynthesis in fungi, euglena, and certain archaebacteria occurs through the a-aminoadipate pathway. 1 Enzymes in the first steps of this pathway have been proposed as potential targets for the development of antifungal therapies, as they are absent in animals but are conserved in several pathogenic fungi species, including Candida, Cryptococcus, and Aspergillus. 2 One potential antifungal target in the a-aminoadipate pathway is the third enzyme in the pathway, homoisocitrate dehydrogenase (HICDH), which catalyzes the divalent metaldependent conversion of homoisocitrate to 2-oxoadipate (2-OA) using nicotinamide adenine dinucleotide (NAD 1 ) as a cofactor. 1 HICDH belongs to a family of b-hydroxyacid oxidative decarboxylases that includes malate dehydrogenase, tartrate dehydrogenase, 6-phosphogluconate dehydrogenase, isocitrate dehydrogenase (ICDH), and 3-isopropylmalte dehydrogenase (IPMDH). ICDH and IPMDH are wellcharacterized enzymes that catalyze the decarboxylation of isocitrate to yield 2-oxoglutarate (2-OG) in the citric acid cycle and the conversion of 3-isopropylmalate to 2-oxoisovalerate in the leucine biosynthetic pathway, respectively. 3 Recent structural and biochemical studies of HICDH reveal that this enzyme shares sequence, structural, and mechanistic homology with ICDH and IPMDH. [3] [4] [5] [6] [7] To date, the only published structures of HICDH are from the archaebacteria Thermus thermophilus (TtHICDH). 6,8 Fungal HICDHs diverge from TtHICDH in several aspects, including their thermal stability, oligomerization state, and substrate specificity, thus warranting further characterization. To gain insights into these differences, we determined crystal structures of a fungal Schizosaccharomyces pombe HICDH (SpHICDH) as an apoenzyme and as a binary complex with the additive tripeptide glycyl-glycyl-glycine (GGG) to 1.55 Å and 1.85 Å resolution, respectively. Finally, a comparison of the SpHICDH and TtHICDH structures reveal differences in their active sites that help explain the variations in their respective substrate specificities.
MATERIALS AND METHODS

Cloning, expression, and purification
Full length HICDH encoded by the Lys12 1 gene in S. pombe was amplified from the genomic clone SPAC31G5.04 (Sanger Institute) and was subcloned into a modified pET15b N-terminal 6xHIS-tag expression vector (Novagen) that contains a tobacco etch virus protease cleavage site. The enzyme was overexpressed in the Rosetta 2 strain (EMD Biosciences) by induction with 0.1 mM isopropyl b-D-1-thiogalactopyranoside at 228C for 16 h. Cells were resuspended in 50 mM sodium phosphate, pH 7.0, 500 mM NaCl, 5 mM b-mercaptoethanol and were lysed with lysozyme followed by sonication. Soluble enzyme was purified on a Talon (Clontech) Co(II) column, and the 6xHIS tag was removed by incubating with tobacco etch virus protease during dialysis overnight against 50 mM sodium phosphate, pH 7.0, 150 mM NaCl, and 5 mM b-mercaptoethanol. The Histagged protease was removed by passing the sample over a second Talon Co(II) column. SpHICDH was further purified by gel filtration via isocratic elution with 50 mM sodium phosphate, pH 7.0, 150 mM NaCl, and 1 mM tris(2-carboxyethyl)phosphine on a Superdex 200 column (GE healthcare). The protein was concentrated to 100-120 mg/mL (A 280 , e 517,420) and stored at 2808C.
Crystallization, data collection, and structure determination Crystals of SpHICDH were initially obtained by vapor diffusion in a condition with 0.2M lithium acetate and 20% (w/v) PEG 3350. The Additive Screen HT (Hampton Research) was used to determine that the addition of 30 mM GGG improved crystal quality. Optimization was performed at 208C in hanging drops composed of 1.5 lL of 25 mg/mL SpHICDH, 1.5 mM 2-OA, 60 mM GGG as an additive and 1.5 lL crystallization solution (0.22M lithium acetate and 18% (w/v) PEG 3350). SpHICDH was also crystallized by hanging drop vapor diffusion using 1 lL of 15-24 mg/mL SpHICDH, 2 mM MgCl 2 , 6.6 mM 2-OA, and 2 mM NAD 1 in 1 lL 0.1-0.25M lithium acetate, 12-16% PEG 3350. Crystals were cryoprotected in their crystallization solution supplemented with 20% glycerol and subsequently frozen in liquid nitrogen. Diffraction data were collected at LS-CAT, beamline 21ID-G at the Advanced Photon Source (Argonne National Labs), and data sets were integrated and scaled using HKL2000 9 (Table I) . A model of SpHICDH was generated in Chainsaw 10 from the sequence alignment of SpHICDH and TtHICDH and the coordinates of the TtHICDH structure (PDB 1X0L), 6 which was subsequently used as a search model for molecular replacement in MOLREP. 11 The model of SpHICDH bound to GGG was built in Coot 12 and refined in REFMAC 13 using TLS refinement. 14 This structure was used as a model for molecular replacement for SpHICDH apoenzyme crystallized in the presence of MgCl 2 , 2-OA, and NAD
1
, which was built and refined as described for the SpHICDH-GGG complex. The final models were validated using Molprobity 15 (Table I) . Root mean square deviations (RMSDs) were calculated for Ca atoms using SSM Superpose in Coot. 12 A simulated annealing omit map of GGG was generated in CNS 16 , and structural figures were created using MacPy-MOL (The PyMOL Molecular Graphics System, Schrö-dinger, LLC.)
RESULTS AND DISCUSSION
Overall structure of SpHICDH
The crystal structures of SpHICDH apoenzyme and complex with GGG were determined by molecular replacement to 1.55 Å and 1.85 Å , respectively (Table I) allel b-sheet at the dimer interface (residues 130-156) [ Fig. 1(A) ]. The secondary structure of a monomer of SpHICDH adopts a modified Rossmann fold 17 with 10 b-strands (b1-b5 and b8-b12) creating a mixed parallel and antiparallel b-sheet [ Fig. 1(B) ]. The remaining two b-strands (b6-b7) compose the clasp domain, which interacts with the adjacent monomer. Additional interactions at the dimer interface are predominantly mediated through the formation of a four-helix bundle between a7 and a8 from both monomers. This fold is homologous to other b-hydroxyacid oxidative decarboxylases includ- Fig.  1(C) ]. Each of these enzymes adopts a closed conformation. The closed and open forms of these enzymes refer to the width of the NADH binding pocket, which is located in a cleft between the large and small domains below the active site [Fig 1(A) ]. For example, the EcICHD apoenzyme has been crystallized in the open and closed states, whereas substrate-bound EcICHD adopts a closed form, which is a result of a $168 rotation of the large domain relative to the small domain that narrows the NADH binding cleft 17,22 . The major difference between SpHICDH and other b-hydroxyacid 
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oxidative decarboxylases is the conformation of the clasp domain and the loop region following b4. The 3 10 -helix preceding the clasp also differs in its orientation between SpHICDH and TtHICDH apoenzyme (discussed below).
Active site of SpHICDH
The active site of SpHICDH is located in a cleft between the small and large domains of one monomer and also contains residues from the small domain of the neighboring monomer. [ Fig. 1(A) The residues in the active site responsible for substrate binding and catalysis have been identified through homology with ICDH and IPMDH and by biochemical characterization of S. cerevisiae HICDH (ScHICDH). 3 A lysine-tyrosine pair composed of 0 and Tyr-133 in SpHICDH (the prime ( 0 ) denotes a residue in the adjacent monomer) have been implicated in the acid-base catalyzed reaction that converts homoisocitrate to 2-OA, based on kinetic studies of ScHICDH [ Fig. 2(A) ]. 5 Additionally, three conserved aspartate residues (Asp232 0 , Asp256, and Asp260) have been proposed to coordinate the divalent metal ion necessary for catalysis. 6 Because SpHICDH adopts a closed conformation in the absence of substrates, its structure can be superimposed with that of an EcICDH-isocitrate complex 25 to gain insight into HICDH substrate recognition. Homoisocitrate is predicted to bind in a similar orientation as isocitrate, with its C1 carboxylate group and 2-hydroxyl groups coordinated to the active site metal ion. Three structurally conserved arginine residues (Arg97, Arg107, and Arg126) further stabilize the substrate through interactions with its C1 and C6 carboxylate groups [ Fig. 2(A) ]. To visualize the binding position of the second substrate, NAD 1 , a product complex of HICDH bound to 2-OA, NADH, and Mg(II) was modeled by aligning the active site residues to that of a product complex of mitochondrial ScICDH bound to NADPH and 2-OG 19 [Fig 2(B) ]. The modeled NADH binds in the active site cleft, adjacent to the product 2-OA, and is flanked by a9 and the loop between b3 and a4 of one monomer and a7 of the adjacent monomer [ Figs. 1(B) and 2(B) ]. The modeled NADH fits well into the active site cleft of SpHICDH; however, there is a clash between the ribose hydroxyl groups of the nicotinamide mononucleotide of NADH and Ser81 located in the b3-a4 loop of the protein, suggesting that a conformational change of this loop is required for coenzyme binding. In summary, the structural alignments illustrate that the active site residues of SpHICDH responsible for substrate binding and catalysis are conserved with the residues in other b-hydroxyacid oxidative decarboxylases.
Unexpectedly, we observed that the tripeptide additive GGG binds in the active site of SpHICDH. Two conserved arginine residues (Arg97 and Arg126), which are proposed to interact with homoisocitrate, form contacts with GGG through a network of direct and water-mediated hydrogen bonds [ Fig. 2(C) ]. The tripeptide is further stabilized by hydrogen bonding to the backbone atoms of residues Ser85, Val87, and Gly89, which are located in the loop between b3 and a4. Additional hydrogen bonds occur between the a-amine group of GGG and Glu285 and Pro286. Together, these interactions orient the GGG tripeptide into a similar location as the modeled NADH and 2-OA products [Supporting Information Fig. S1 ]. Specifically, the backbone carbonyl of the second glycine is nearly superimposable with the modeled nitrogen in the ring of the nicotinamide moiety of NADH. Additionally, the Cterminal carboxylate of GGG is positioned between the amide nitrogen in the nicotinamide group of NADH and the C1 carboxylate of 2-OA, respectively.
Comparison of SpHICDH to TtHICDH
A comparison of the SpHICDH and TtHICDH structures reveals some key differences between the fungal and archaeal enzymes. First, the two enzymes exhibit distinct oligomerization states. SpHICDH eluted as a homodimer in size exclusion chromatography (data not shown) and crystallized in the same oligomerization state (Table I) . In contrast, TtHICDH functions as a homotetramer, with the clasp domain of two dimers forming hydrophobic intersubunit interactions. 6,7 This tetramerization state is presumably unique to archaeal HICHDs and may enhance the thermostability of the enzyme, as a mutation that disrupts tetramerization exhibits a lower thermal inactivation temperature. 6 Moreover, the active site conformation differs between SpHICDH and TtHICDH apoenzyme despite their homologous structures [Figs. 1(C) and 2(D)]. In TtHICDH, the active site adopts a nonproductive conformation in which Tyr125 is flipped out of the active site cleft [ Fig. 2(D) ]. This observation lead Miayzaki et al. to speculate that either substrate binding is coupled to a conformational change in the active site or the TtHICDH structure represents a nonphysiologically relevant structure, possibly induced by the low pH of the crystallization condition. 6 Conversely, in SpHICDH, the corresponding tyrosine (Tyr133) is orientated in a catalytically competent conformation due to a shift of the 3 10 helix toward b6 and b7 of the clasp domain. In a recent study, the structure of TtHICDH in complex with a designed inhibitor is reported. 8 Similar to SpHICDH, the catalytic tyrosine (Tyr125) is flipped inward and interacts with the inhibitor, indicating that it is important for catalysis, and possibly substrate binding. These finding suggest that the SpHICDH active site adopts a conformation that is conducive to substrate binding, whereas the nonproductive configuration observed in the TtHICDH apoenzyme structure may be a consequence of the crystallization condition. Further structural studies of HICDH substrate and product complexes are needed to ascertain the extent of the conformational changes that occur in the active site during ligand binding.
In addition to variations in their oligomerization state and active site conformation, the substrate specificities of the fungal and archaeal HICDHs also differ. TtHICDH utilizes both isocitrate and homoisocitrate as substrates, whereas yeast HICDHs display greater specificity for homoisocitrate versus isocitrate. 4,7,26 Mutagenesis studies in TtHICDH determined that substrate specificity is governed by a key active site residue, Arg85 in TtHICDH or Val94 in SpHICDH, which occupy the same position in their active sites [ Fig. 2(D) ]. 7 This observation is particularly interesting in that the structurally equivalent residue in ICDHs is also a valine. ICDH specificity towards its preferred substrate is instead governed by serine and asparagine residues (Ser113 and Asn115 in EcICDH), which form interactions with the C5 carboxylate of isocitrate [Supporting Information Fig. S2] . 25,27 The serine residue is conserved in HICDHs, but the asparagine is an isoleucine in yeast and archaeal HICDHs. Based on an SpHICDH-isocitrate model [ Fig. 2(A) ], Val94 may form van der Waals interactions to isocitrate, whereas in TtHICDH the corresponding Arg85 could potentially hydrogen bond to C5 carboxylate of isocitrate, equivalent to the interaction of the asparagine residue in ICDHs. Thus, this model offers a potential explanation for the ability of TtHICDH to efficiently oxidize both citrate and homocitrate. In summary, these observations suggest potential routes to exploit structural variations between the active sites of fungal and other b-hydroxyacid oxidative decarboxylases to design HICDH-specific inhibitors.
